Cover Image
市場調查報告書

新的眼壓下降藥及設備

Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026

出版商 ROOTS ANALYSIS 商品編碼 367979
出版日期 內容資訊 英文 228 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
新的眼壓下降藥及設備 Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026
出版日期: 2016年08月26日 內容資訊: 英文 228 Pages
簡介

本報告提供高眼壓的新的治療藥、治療用設備、外科的治療的市場調查,高眼壓的要素與相關疾病,現在可以利用的治療選擇其缺點,新的治療藥及設備的開發平台趨勢,主要企業產品簡介,主要藥物及設備的銷售額預測,MIGS (微創青光眼手術) 用設備的詳細分析等彙整資料。

第1章 序章

第2章 摘要整理

第3章 簡介

  • 概要
  • 眼結構
  • 水樣液動態
  • 高眼壓的原因
  • 高眼壓的相關疾病
    • 高眼壓症
    • 青光眼
    • 視網膜動脈閉塞症
  • 治療選擇:高眼壓症、青光眼
    • 內科的治療
    • 雷射治療
      • Argon小樑整型術 (ALT)
      • 選擇性雷射小樑網整型術 (SLT)
    • 外科的治療
  • 目前治療選擇的缺點
  • 新的眼壓下降藥目標
  • 新的眼壓下降設備
    • 外科的設備
    • 緩釋性藥物輸送設備

第4章 市場環境:新的藥物

  • 本章概要、範圍
  • 新的高眼壓治療藥:臨床、前臨床管線欄
    • 各最高開發階段
    • 各作用機制
    • 疾病的各子類型
    • 各投藥途徑
    • 各投藥計劃

第5章 市場環境:新的設備

  • 本章概要
  • 新的高眼壓治療設備:管線欄分析
    • 各最高開發階段
    • 各目的
    • 各類別
    • 各方法途徑
    • 緩釋性藥物輸送設備

第6章 企業、產品簡介

  • 本章概要
  • Aerie Pharmaceuticals
  • Inotek Pharmaceuticals
  • 興和
  • 參天製藥
  • Valeant Pharmaceuticals International

第7章 企業、設備簡介

  • 本章概要
  • Alcon (Novartis Company)
  • Allergan
  • Ellex
  • Glaukos
  • InnFocus
  • iSTAR Medical
  • Ivantis
  • New World Medical
  • Sight Sciences

第8章 市場預測

  • 本章概要
  • 預測手法、前提條件
  • 青光眼整體市場的變化與預測
    • 藥物:銷售額預測
      • Glanatec ™ (Ripasudil / K-115)
      • Vesneo ™ (Latanoprostene bunod)
      • Rhopressa ™ (AR-13224 / Netarsudil Mesylate)
      • Trabodenoson (INO-8875)
      • Roclatan ™ (PG324)
      • DE-117
    • 緩釋性藥物輸送設備:銷售額預測
      • Bimatoprost SR
      • Helios ™ Insert (Bimatoprost Ring)
      • Punctal Plug Delivery System
      • ENV 515
      • OTX-TP
      • iDose ™
    • 外科用設備:銷售額預測
      • MIGS (微創青光眼手術) 用設備
      • 非MIGS用設備

第9章 MIGS用設備:雷達表分析

  • 本章概要
  • MIGS用設備:概要
  • MIGS用設備:核準時間軸
  • MIGS用設備:競爭環境
  • 比較分析
    • 植入
    • 切除設備

第10章 總論

第11章 採訪

第12章 附錄1:圖表

第13章 附錄2:企業清單

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10065

An imbalance in the production and / or drainage of aqueous humor within the eye is known to lead to an increase in intraocular pressure (IOP). Acutely elevated IOP, a condition broadly known as ocular hypertension, may either lead to the expulsion of ocular contents through a traumatic opening or result in a number of clinical conditions / disorders including glaucoma. Currently available treatment options include ocular hypotensive medications, laser therapy and surgical interventions. However, these treatment modalities are known to be associated with a number of complications and adverse events. Amongst these, poor adherence rates are a major concern in patients who are on ocular hypotensive medications; an estimated 50% of patients do not adhere to the therapeutic regimen prescribed to them. Laser therapies are known to lose their efficacy over time. It has been observed that the disease is controlled only in around 50% of patients who have been treated with some form of laser therapy; the effect usually wears off after a period of five years. Traditional surgical procedures, such as filtration procedures, glaucoma drainage devices (GDDs) and cyclodestructive procedures, are also known to have various risks and complications associated with them. Therefore, in the current scenario, multiple challenges exist as far as the treatment of elevated IOP is concerned.

A better understanding of the complex pathways involved in aqueous humor dynamics has resulted in the identification of many novel targets for maintaining ocular homeostasis. These novel targets have led to the development of a number of innovative therapeutic options for lowering elevated IOP. Specifically, to address poor patient compliance, a number of players are developing sustained release devices (implants, punctal plugs or contact lenses) so that the patient is not required to self-medicate on a regular basis. Similarly, the landscape of surgical interventions is also witnessing a lot of change with the emergence of safer, reproducible and less invasive treatment options. These novel surgical interventions include minimally-invasive glaucoma surgery (MIGS), blebless ab externo glaucoma surgery (BAGS), ab externo bleb surgery (ABS), minimally invasive micro sclerostomy (MIMS), non-penetrating glaucoma surgery (NPGS) and non-invasive glaucoma procedure (NIGP).

Synopsis:

The ‘Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026' report provides an extensive study of the emerging market of such novel drugs, devices and surgical procedures for the treatment of elevated IOP. The focus of this study is on the applications of these novel treatment options, both marketed and under development, and their likely mid to long term evolution. These treatment options claim to provide consistent benefits related to IOP lowering and are anticipated to gain widespread adoption in the foreseen future.

The report covers various aspects of this market; some of these are outlined below:

  • A detailed assessment of the current market landscape of novel drugs and devices, key players involved, the status of development of various pipeline products and the target patient segments.
  • Comprehensive profiles covering mechanism of action, clinical trial details and associated developments of Rho-associated protein kinase (ROCK) inhibitors, ROCK / norepinephrine transporter (NET) inhibitors and NO donating prostaglandins in late stage of development.
  • Comprehensive profiles highlighting the IOP reduction approach, key performance drivers, safety and efficacy of novel surgical procedures that have been approved or are in advanced stages of development.
  • Comparative analysis of MIGS devices based on various parameters such as drainage route, length of the implant, involvement of conjunctiva, type of procedure (ab interno or ab externo), procedure duration and ability of the device to treat 360 degrees.
  • An informed view on the likely future evolution of such novel drugs, sustained release drug delivery devices and surgical procedures over the next decade. This includes sales forecasts of six novel drugs, including Rhopressa, Roclatan and Vesneo. Similarly, we have presented our view on the future market size of six drug delivery devices, including Bimatoprost SR, OTX-TP and punctal plug delivery system. We have also determined the likely future revenues for MIGS and non-MIGS surgical devices (BAGS, ABS, NIGP and NPGS).

To account for the uncertainties in the market, we have provided three market forecast scenarios that represent three different tracks of the market's evolution. Given the current unmet need for safer and more effective therapeutic options and the rich pipeline of novel drugs and devices, we expect this market to witness significant growth in the coming few years.

Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Bob Butchofsky (Founder and CEO, Mati Therapeutics), Suzana Nahum Zilberberg (CEO, Bio-Light Life Sciences), Ronen Castro (CEO, IOPtima) and Donald Schwartz (CEO and President, Eye Sonix).

Example Highlights

  • 1. Glaucoma is the second leading cause of blindness, worldwide, after cataract. It is estimated that, by 2020, around 79.6 million people in the world will have glaucoma. Specifically, in the US, it is estimated that, by 2020, 4 million people will have glaucoma with 50% cases left undiagnosed.
  • 2. Currently available treatment options (ocular hypotensive medications, laser therapy and surgical interventions) are associated with a number of complications and adverse events. Known drawbacks include poor patient compliance, loss of adequate response, intolerable ocular and systemic adverse effects, and degradation of quality of life.
  • 3. Rho-associated protein kinase (ROCK) inhibitors, ROCK / norepinephrine transporter (NET) inhibitors, adenosine receptor agonists, adenosine A3 receptor antagonists and Nitric oxide (NO) donors have emerged as novel drug classes in this field. In fact, one drug (Glanatec from Kowa Company) is already available in the Japanese market; more than 20 are in clinical development and rest are in the preclinical / discovery phase.
  • 4. Examples of players with candidate molecules in the late stages development include Aerie Pharmaceuticals (Rhopressa™ and Roclatan™), Inotek Pharmaceuticals (Trabodenoson), Santen Pharmaceutical (DE-117) and Valeant Pharmaceuticals (Vesneo™). In addition, a number of other start-ups are exploring the potential in this domain.
  • 5. 13 novel drug delivery devices are under development as sustained release systems. Specifically, Bimatoprost SRfrom Allergan is already in Phase III of clinical development. A number of other devices, currently in early stages of development, are likely to provide a credible alternative to tackle the challenges associated with poor patient compliance.
  • 6. Advances in glaucoma surgery have led to the emergence of several novel surgical devices. There are over 30 novel surgical devices that have been developed / are being developed for the treatment of elevatedIOP. MIGS devices currently represent a growing portion of the glaucoma surgery market; these have been shown to provide better results compared to traditional trabeculectomy procedures.
  • 7. Over the course of next ten years, the market for novel drugs is likely to grow at a relatively higher annualized rate of 83.9%. Similarly, we expect significant growth in the market of sustained release drug delivery devices and novel surgical devices. Combined, such novel drugs and devices are expected to cater to over 65% of the total glaucoma market by 2026.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary and offers a high level view on where the market for IOP lowering novel drugs and devices is headed in the mid to long term.

Chapter 3 is a general introduction to IOP and the various diseases associated with elevated IOP. It contains detailed discussions on aqueous humor dynamics and the various factors responsible for an increase in IOP. The chapter also outlines the currently available treatment modalities for IOP related diseases and their shortcomings.

Chapter 4 includes information on novel drugs that are either already available or being evaluated in different stages of development for the treatment of IOP. In this chapter, we have presented a comprehensive pipeline of all such products that we identified during our research. It presents an analysis of the aforementioned pipeline based on a number of different parameters, including phase of development, mechanism of action, disease sub-type, route of administration and dosage schedule.

Chapter 5 presents information on the various types of novel devices (surgical and drug delivery devices) that are either already available in the market or being evaluated in different stages of development. Similar to the previous chapter, we have presented a comprehensive pipeline of all relevant devices that we came across during our research. The chapter provides an analysis of the pipeline based on the phase of development of the product, its purpose, the category of devices it belongs to and the approach / pathway it employs for IOP reduction. In addition, we have added a separate section on drug delivery devices highlighting details such as the type of drug delivered and the nature of implant (biodegradable or non-biodegradable).

Chapter 6 provides detailed company profiles of the prominent players that are involved in investigating novel drugs for the treatment of elevated IOP. Each company profile includes a brief overview of the company, its financial information, key performance drivers, and its future outlook and strategy. In addition, the profiles cover details of late stage candidate therapies, such as Rho-associated protein kinase (ROCK) inhibitors, ROCK / norepinephrine transporter (NET) inhibitors and NO donating prostaglandins, which are being evaluated for the treatment of elevated IOP. These details include an overview of the product, its mechanism of action, collaborations / partnerships specific to the particular drug, key developmental events and the associated clinical trials landscape.

Chapter 7 provides details on some of the important players involved in the development of MIGS and BAGS devices. Each company profile includes a brief overview of the company, funding instances,financial information, key performance drivers, and its future outlook and strategy. In addition, the profiles cover details of company's approved / clinical stage devices. These details include a brief overview of the product, its specifications (size, shape, material and surgical procedure used to insert the device into the eye), the IOP reduction approach it follows, details of its clinical studies, and efficacy and safety data.

Chapter 8 offers a comprehensive perspective on how the market for novel drugs and devices in this field is likely to evolve over the next ten years. In this chapter, we have forecasted the sales of six novel drugs, including Rhopressa, Roclatan and Vesneo. Similarly, we have presented our view on the future market size of six drug delivery devices, which include Bimatoprost SR, OTX-TP and punctal plug delivery system. We have also determined the likely future revenues for MIGS and non-MIGS devices (BAGS, ABS, NIGP and NPGS). Due to uncertainties surrounding some of the key assumptions made within our forecast model, we have presented three different evolutionary scenarios for the overall market, namely the base, conservative and optimistic scenarios.

Chapter 9 provides information on MIGS devices covering the salient features that distinguish them from traditional surgical interventions. The chapter includes an overview of the current market landscape of MIGS devices and presents an approval timeline highlighting all the approved devices of this nature. We have also presented a comparative spider web analysis of MIGS devices (for both approved and under development devices) based on different parameters, such as drainage route, length of the implant, involvement of conjunctiva, type of procedure (ab interno or ab externo), duration of the procedure, the ability to treat entire Schlemm's canal and the target patient segment.

Chapter 10 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion regarding the market based on the research and analysis described in the previous chapters.

Chapter 11 is a collection of interview transcripts of our discussions with some of the key players in this industry. We have presented the details of our conversations with Bob Butchofsky (Founder and CEO, Mati Therapeutics), Suzana Nahum Zilberberg (CEO, Bio-Light Life Sciences), Ronen Castro (CEO, IOPtima) and Donald Schwartz (CEO and President, Eye Sonix).

Chapters 12 and 13 are appendices, which provide tabulated data and a list of companies that are mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview
  • 3.2. Structure of the Eye
  • 3.3. Aqueous Humor Dynamics
    • 3.3.1. Aqueous Humor Production
    • 3.3.2. Aqueous Humor Drainage
  • 3.4. Factors Responsible for Elevated IOP
  • 3.5. Diseases Associated with Elevated IOP
    • 3.5.1. Ocular Hypertension
    • 3.5.2. Glaucoma
    • 3.5.3. Retinal Artery Occlusion
  • 3.6. Treatment Options: Ocular Hypertension and Glaucoma
    • 3.6.1. Medical Treatment
    • 3.6.2. Laser Therapy
      • 3.6.2.1. Argon Laser Trabeculoplasty (ALT)
      • 3.6.2.2. Selective Laser Trabeculoplasty (SLT)
    • 3.6.3. Surgical Treatment
  • 3.7. Drawbacks of Currently Available Treatment Options
    • 3.7.1. Drawbacks of Medical Treatment
    • 3.7.2. Drawbacks of Laser Therapy
    • 3.7.3. Drawbacks of Surgical Treatment
  • 3.8. Novel Therapeutic Targets for Lowering IOP
  • 3.9. Novel Devices for Lowering IOP
    • 3.9.1. Novel Surgical Devices
    • 3.9.2. Novel Sustained Release Drug Delivery Devices

4. MARKET LANDSCAPE: NOVEL DRUGS

  • 4.1. Chapter Overview and Scope
  • 4.2. Novel Drugs to Treat Elevated IOP: Clinical and Preclinical Pipeline
    • 4.2.1. Novel Drugs to Treat Elevated IOP: Analysis by Highest Phase of Development
    • 4.2.2. Novel Drugs to Treat Elevated IOP: Analysis by Mechanism of Action
    • 4.2.3. Novel Drugs to Treat Elevated IOP: Analysis by Disease Sub-type
    • 4.2.4. Novel Drugs to Treat Elevated IOP: Analysis by Route of Administration
    • 4.2.5. Novel Drugs to Treat Elevated IOP: Analysis by Dosing Schedule

5. MARKET LANDSCAPE: NOVEL DEVICES

  • 5.1. Chapter Overview
  • 5.2. Novel Devices to Treat Elevated IOP: Pipeline Analysis
    • 5.2.1. Novel Devices to Treat Elevated IOP: Analysis by Highest Phase of Development
    • 5.2.2. Novel Devices to Treat Elevated IOP: Analysis by Purpose of the Device
    • 5.2.3. Novel Devices to Treat Elevated IOP: Analysis by Category of the Device
    • 5.2.4. Novel Devices to Treat Elevated IOP: Analysis by Approach / Pathway for IOP Reduction
    • 5.2.5. Sustained Release Drug Delivery Devices

6. COMPANY AND DRUG PROFILES

  • 6.1. Chapter Overview
  • 6.2. Aerie Pharmaceuticals
    • 6.2.1. Company Overview
    • 6.2.2. Funding
    • 6.2.3. Future Outlook
    • 6.2.4. Product Profile: Rhopressa™ (AR-13224 / Netarsudil Mesylate)
      • 6.2.4.1. Drug Specification
      • 6.2.4.2. Mechanism of Action
      • 6.2.4.3. Key Development Events
    • 6.2.5. Product Profile: Roclatan™ (PG324)
      • 6.2.5.1. Drug Specification
      • 6.2.5.2. Mechanism of Action
      • 6.2.5.3. Key Development Events
  • 6.3. Inotek Pharmaceuticals
    • 6.3.1. Company Overview`
    • 6.3.2. Funding
    • 6.3.3. Product Profile: Trabodenoson (INO-8875)
      • 6.3.3.1. Drug Specification
      • 6.3.3.2. Mechanism of Action
      • 6.3.3.3. Key Development Events
  • 6.4. Kowa Company
    • 6.4.1. Company Overview
    • 6.4.2. Product Profile: Glanatec™ (Ripasudil / K-115)
      • 6.4.2.1. Drug Specification
      • 6.4.2.2. Mechanism of Action
      • 6.4.2.3. Collaboration with D. Western Therapeutics Institute
      • 6.4.2.4. Key Development Events
  • 6.5. Santen Pharmaceutical
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Future Outlook
    • 6.5.4. Product Profile: DE-117
      • 6.5.4.1. Drug Specification
      • 6.5.4.2. Mechanism of Action
      • 6.5.4.3. Collaboration with Ube Industries
      • 6.5.4.4. Key Development Events
    • 6.5.5. Product Profile: Sepetaprost (ONO-9054 / DE-126)
      • 6.5.5.1. Drug Specification
      • 6.5.5.2. Mechanism of Action
      • 6.5.5.3. Collaboration with Ono Pharmaceutical
      • 6.5.5.4. Key Development Events
  • 6.6. Valeant Pharmaceuticals International
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Future Outlook
    • 6.6.4. Product Profile: Vesneo™ (Latanoprostene Bunod)
      • 6.6.4.1. Drug Specification
      • 6.6.4.2. Mechanism of Action
      • 6.6.4.3. Collaboration with NicOx
      • 6.6.4.4. Key Development Events

7. COMPANY AND DEVICE PROFILES

  • 7.1. Chapter Overview
  • 7.2. Alcon (a Novartis Company)
    • 7.2.1. Company Overview
    • 7.2.2. Acquisition of Transcend Medical
    • 7.2.3. Financial Information
    • 7.2.4. CyPass® Micro-Stent
      • 7.2.4.1. Product Overview
      • 7.2.4.2. IOP Reduction Approach
      • 7.2.4.3. Product Specifications
      • 7.2.4.4. Key Development Events
      • 7.2.4.5. Clinical Studies
      • 7.2.4.6. Key Clinical Results
  • 7.3. Allergan
    • 7.3.1. Company Overview
    • 7.3.2. Acquisition of AqueSys
    • 7.3.3. Financial Information
    • 7.3.4. Future Outlook
    • 7.3.5. XEN™ Gel Stent
      • 7.3.5.1. Product Overview
      • 7.3.5.2. IOP Reduction Approach
      • 7.3.5.3. Product Specifications
      • 7.3.5.4. Clinical Studies
      • 7.3.5.5. Key Clinical Results
  • 7.4. Ellex
    • 7.4.1. Company Overview
    • 7.4.2. Acquisition of Canaloplasty Business of iScience Interventional
    • 7.4.3. Financial Information
    • 7.4.4. iTrack™ 250A (to Perform Traditional Canaloplasty)
      • 7.4.4.1. Product Overview
      • 7.4.4.2. IOP Reduction Approach
      • 7.4.4.3. Product Specifications
      • 7.4.4.4. Key Clinical Results
    • 7.4.5. iTrack™ 250A (to Perform ABiC)
      • 7.4.5.1. Product Overview
      • 7.4.5.2. Approach of IOP Reduction
      • 7.4.5.3. Product Specifications
      • 7.4.5.4. Key Clinical Results
  • 7.5. Glaukos
    • 7.5.1. Company Overview
    • 7.5.2. Financial Information
    • 7.5.3. Future Outlook
    • 7.5.4. iStent®
    • 7.5.4.1. Product Overview
      • 7.5.4.2. IOP Reduction Approach
      • 7.5.4.3. Product Specifications
      • 7.5.4.4. Key Development Events
      • 7.5.4.5. Clinical Studies
      • 7.5.4.6. Key Clinical Results
    • 7.5.5. iStent inject®
      • 7.5.5.1. Product Overview
      • 7.5.5.2. IOP Reduction Approach
      • 7.5.5.3. Product Specifications
      • 7.5.5.4. Key Development Events
      • 7.5.5.5. Clinical Studies
      • 7.5.5.6. Key Clinical Results
    • 7.5.6. iStent Supra®
      • 7.5.6.1. Product Overview
      • 7.5.6.2. IOP Reduction Approach
      • 7.5.6.3. Product Specifications
      • 7.5.6.4. Key Development Events
      • 7.5.6.5. Clinical Studies
      • 7.5.6.6. Key Clinical Results
  • 7.6. InnFocus
    • 7.6.1. Company Overview
    • 7.6.2. Funding
    • 7.6.3. InnFocus Microshunt™
      • 7.6.3.1. Product Overview
      • 7.6.3.2. IOP Reduction Approach
      • 7.6.3.3. Product Specifications
      • 7.6.3.4. Key Development Events
      • 7.6.3.5. Clinical Studies
      • 7.6.3.6. Key Clinical Results
  • 7.7. iSTAR Medical
    • 7.7.1. Company Overview
    • 7.7.2. Funding
    • 7.7.3. STARflo™ Glaucoma Implant
      • 7.7.3.1. Product Overview
      • 7.7.3.2. IOP Reduction Approach
      • 7.7.3.3. Product Specifications
      • 7.7.3.4. Key Development Events
      • 7.7.3.5. Regional Collaborations
      • 7.7.3.6. Clinical Studies
  • 7.8. Ivantis
    • 7.8.1. Company Overview
    • 7.8.2. Funding
    • 7.8.3. Hydrus™ Microstent
      • 7.8.3.1. Product Overview
      • 7.8.3.2. IOP Reduction Approach
      • 7.8.3.3. Product Specifications
      • 7.8.3.4. Key Development Events
      • 7.8.3.5. Clinical Studies
      • 7.8.3.6. Key Clinical Results
  • 7.9. New World Medical
    • 7.9.1. Company Overview
    • 7.9.2. Kahook Dual Blade™
      • 7.9.2.1. Product Overview
      • 7.9.2.2. IOP Reduction Approach
      • 7.9.2.3. Product Specifications
  • 7.10. Sight Sciences
    • 7.10.1. Company Overview
    • 7.10.2. Funding
    • 7.10.3. TRAB™360
      • 7.10.3.1. Product Overview
      • 7.10.3.2. IOP Reduction Approach
      • 7.10.3.3. Product Specifications
      • 7.10.3.4. Key Clinical Results
    • 7.10.4. VISCO™360
      • 7.10.4.1. Product Overview
      • 7.10.4.2. IOP Reduction Approach
      • 7.10.4.3. Product Specifications

8. MARKET FORECAST

  • 8.1. Chapter Overview
  • 8.2. Forecast Methodology and Assumptions
  • 8.3. Overall Glaucoma Market, 2016 - 2026
    • 8.3.1. Novel Drugs Market, 2016 - 2026
      • 8.3.1.1. Glanatec™ (Ripasudil / K-115): Sales Forecast
      • 8.3.1.2. Vesneo™ (Latanoprostene bunod): Sales Forecast
      • 8.3.1.3. Rhopressa™ (AR-13224 / Netarsudil Mesylate): Sales Forecast
      • 8.3.1.4. Trabodenoson (INO-8875): Sales Forecast
      • 8.3.1.5. Roclatan™ (PG324): Sales Forecast
      • 8.3.1.6. DE-117: Sales Forecast
    • 8.3.2. Sustained Release Drug Delivery Devices Market
      • 8.3.2.1. Bimatoprost SR: Sales Forecast
      • 8.3.2.2. Helios™ Insert(Bimatoprost Ring): Sales Forecast
      • 8.3.2.3. Punctal Plug Delivery System Sales Forecast
      • 8.3.2.4. ENV 515: Sales Forecast
      • 8.3.2.5. OTX-TP: Sales Forecast
      • 8.3.2.6. iDose™: Sales Forecast
    • 8.3.3. Novel Surgical Devices Market, 2016 - 2026
      • 8.3.3.1. MIGS Devices: Sales Forecast, 2016 - 2026
      • 8.3.3.2. Non-MIGS Devices: Sales Forecast, 2016 - 2026

9. MIGS DEVICES: COMPARATIVE SPIDER WEB ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. MIGS Devices: An Overview
  • 9.3. MIGS Devices: Approval Timeline
  • 9.4. MIGS Devices: Competitive landscape
  • 9.5. Comparative Analysis of MIGS Devices
    • 9.5.1. Comparative Analysis of Implants
    • 9.5.2. Comparative Analysis of Ablation Devices

10. CONCLUSION

  • 10.1. Novel Drug Classes have Recently Emerged for the Management of IOP
  • 10.2. Sustained Release Devices are Expected to Eradicate Compliance Issues
  • 10.3. Microinvasive Surgery has the Potential to Revolutionize Glaucoma Treatment
  • 10.4. Significant Shift is Likely to Occur in the Overall Market Landscape in the Mid-Long Term
  • 10.5. Concluding Remarks

11. INTERVIEW TRANSCRIPTS

  • 11.1. Chapter Overview
  • 11.2. Bob Butchofsky, Founder and CEO, Mati Therapeutics
  • 11.3. Donald Schwartz, CEO and President, Eye Sonix
  • 11.4. Ronen Castro, CEO, IOPtima
  • 11.5. Suzana Nahum Zilberberg, CEO, Bio-Light Life Sciences

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Novel Surgical Devices: Approaches for IOP Reduction
  • Figure 4.1: Novel Drugs to Treat Elevated IOP: Distribution by Highest Phase of Development
  • Figure 4.2: Novel Drugs to Treat Elevated IOP: Distribution by Mechanism of Action
  • Figure 4.3: Novel Drugs to Treat Elevated IOP: Distribution by Disease Sub-type
  • Figure 4.4: Novel Drugs to Treat Elevated IOP: Distribution by Route of administration
  • Figure 4.5: Novel Drugs to Treat Elevated IOP: Distribution by Dosing Schedule
  • Figure 5.1: Novel Devices to Treat Elevated IOP: Distribution by Highest Phase of Development
  • Figure 5.2: Novel Devices to Treat Elevated IOP: Approved Products in the US and EU
  • Figure 5.3: Novel Devices to Treat Elevated IOP: Distribution by Purpose of the Device
  • Figure 5.4: Novel Devices to Treat Elevated IOP: Distribution by Category of the Device
  • Figure 5.5: Novel Devices to Treat Elevated IOP: Distribution by Approach / Pathway for IOP Reduction
  • Figure 6.1: Rhopressa™: Clinical Development Timeline
  • Figure 6.2: Roclatan™: Clinical Development Timeline
  • Figure 6.3: Trabodenoson: Clinical Development Timeline
  • Figure 6.4: Glanatec™: Clinical Development Timeline
  • Figure 6.5: Santen Annual Revenues, FY 2010 - FY 2015 (JPY Billion)
  • Figure 6.6: DE-117: Clinical Development Timeline
  • Figure 6.7: Sepetaprost: Clinical Development Timeline
  • Figure 6.8: Valeant Pharmaceuticals Annual Revenues, 2010 - 2015 (USD Billion)
  • Figure 6.9: Vesneo™: Clinical Development Timeline
  • Figure 7.1: Alcon Annual Revenues, 2011 - H1 2016 (USD Billion)
  • Figure 7.2: Allergan Annual Revenues, 2011- H1 2016 (USD Billion)
  • Figure 7.3: Ellex Annual Revenues, FY 2011 - FY 2015 (USD Million)
  • Figure 7.4: Glaukos Annual Revenues, 2013 - H1 2016 (USD Million)
  • Figure 8.1: Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 - 2026, Base Scenario (USD Billion)
  • Figure 8.2: Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Base Scenario)
  • Figure 8.3: Novel Drugs Market, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.4: Glanatec™ (Ripasudil / K-115) Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.5: Vesneo™ (Latanoprostene Bunod) Sales Forecast, 2017 - 2026: Base Scenario (USD Billion)
  • Figure 8.6: Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.7: Trabodenoson (INO-8875) Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.8: Roclatan™ (PG324) Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.9: DE-117 Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.10: Sustained Release Devices Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.11: Bimatoprost SR Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.12: Helios™ Insert (Bimatoprost Ring) Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.13: Punctal Plug Delivery System Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.14: ENV515 Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.15: OTX-TP Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.16: iDose™ Sales Forecast: Base Scenario (USD Billion)
  • Figure 8.17: Novel Surgical Devices Market, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.18: MIGS Devices Market, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.19: Non-MIGS Devices Market, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.20: Non-MIGS Devices Market, 2026: Distribution by Device Category
  • Figure 9.1: MIGS Devices: Approval Timeline
  • Figure 9.2: MIGS Devices: Comparative Analysis of Implants
  • Figure 9.3: MIGS Devices: Comparative Analysis of Ablation Devices
  • Figure 10.1: Glaucoma Therapies Market: Distribution by Treatment Modalities, 2016, 2021, and 2026 (USD Billion)

List of Tables:

  • Table 3.1: Eye: Description of Tissue Layers
  • Table 3.2: Currently Available Drugs for Ocular Hypertension and Glaucoma
  • Table 3.3: Currently Available Fixed Combination Treatments
  • Table 3.4: Ocular Adverse Reactions by Drug Class
  • Table 3.5: Systemic Adverse Reactions by Drug Class
  • Table 3.6: New Therapeutic Targets for Lowering IOP
  • Table 4.1: Novel Drugs to Treat Elevated IOP: Marketed and Clinical Pipeline
  • Table 4.2: Novel Drugs to Treat Elevated IOP: Preclinical and Discovery Pipeline
  • Table 5.1: Novel Devices to Treat Elevated IOP: Pipeline
  • Table 5.2: Sustained Release Drug Delivery Devices
  • Table 6.1: Novel Drugs in Advanced Stages of Development
  • Table 6.2: Aerie Pharmaceuticals: Product Candidates to Treat Elevated IOP
  • Table 6.3: Kowa's Pharmaceutical Business Division: Therapeutic Areas and Related Indications
  • Table 6.4: Santen Pharmaceutical: Novel Product Candidates
  • Table 7.1: List of Company and Device Profiles
  • Table 7.2: CyPass® Micro-Stent: Industry Sponsored Clinical Trials
  • Table 7.3: XEN™ Gel Stent: Industry Sponsored Clinical Trials
  • Table 7.4: Ellex: Novel IOP Lowering Devices
  • Table 7.5: Ellex 2015 Sales: Key Market Segments
  • Table 7.6: Glaukos: IOP Lowering Product Portfolio
  • Table 7.7: iStent®: Industry Sponsored Clinical Trials
  • Table 7.8: iStent inject®: Industry Sponsored Clinical Trials
  • Table 7.9: iStent Supra®: Industry Sponsored Clinical Trials
  • Table 7.10: InnFocus Microshunt™: Industry Sponsored Clinical Trials
  • Table 7.11: iSTAR Medical: Devices in Development
  • Table 7.12: iSTAR Medical: Global Distribution Partners
  • Table 7.13: Hydrus™ Microstent: Industry Sponsored Clinical Trials
  • Table 7.14: Sight Sciences: Novel IOP Lowering Devices
  • Table 8.1: Novel Drugs: Estimated Launch Years
  • Table 8.2: Sustained Release Drug Delivery Devices: Estimated Launch Years
  • Table 9.1: MIGS Devices Competitive Landscape
  • Table 9.2: Comparative Analysis of Implants: Details on Parameters
  • Table 9.3: Comparative Analysis of Ablation Devices: Details on Parameters
  • Table 12.1: Novel Drugs to Treat Elevated IOP: Distribution by Highest Phase of Development
  • Table 12.2: Novel Drugs to Treat Elevated IOP: Distribution by Mechanism of Action
  • Table 12.3: Novel Drugs to Treat Elevated IOP: Distribution by Disease Sub-type
  • Table 12.4: Novel Drugs to Treat Elevated IOP: Distribution by Route of administration
  • Table 12.5: Novel Drugs to Treat Elevated IOP: Distribution by Dosing Schedule
  • Table 12.6: Novel Devices to Treat Elevated IOP: Distribution by Highest Phase of Development
  • Table 12.7: Novel Devices: Approved Products in the US and EU
  • Table 12.8: Novel Devices to Treat Elevated IOP: Distribution by Purpose of the Device
  • Table 12.9: Novel Devices to Treat Elevated IOP: Distribution by Approach / Pathway for IOP reduction
  • Table 12.10: Santen Annual Revenues, FY 2010 - FY 2015 (JPY Billion)
  • Table 12.11: Valeant Pharmaceuticals Annual Revenues, 2010 - 2015 (USD Billion)
  • Table 12.12: Alcon Annual Revenues, 2011 - H1 2016 (USD Billion)
  • Table 12.13: Allergan Annual Revenues, 2011- H1 2016 (USD Billion)
  • Table 12.14: Ellex Annual Revenues, FY 2011 - FY 2015 (USD Million)
  • Table 12.15: Glaukos Annual Revenues, 2013 - H1 2016 (USD Million)
  • Table 12.16: Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 - 2026, Base Scenario (USD Billion)
  • Table 12.17: Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 - 2026, Optimistic Scenario (USD Billion)
  • Table 12.18: Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 - 2026, Conservative Scenario (USD Billion)
  • Table 12.19: Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Base Scenario)
  • Table 12.20: Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Optimistic Scenario)
  • Table 12.21: Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Conservative Scenario)
  • Table 12.22: Novel Drugs Market, 2016 - 2026: Base Scenario (USD Billion)
  • Table 12.23: Novel Drugs Market, 2016 - 2026: Optimistic Scenario (USD Billion)
  • Table 12.24: Novel Drugs Market, 2016 - 2026: Conservative Scenario (USD Billion)
  • Table 12.25: Glanatec™ (Ripasudil / K-115) Sales Forecast: Base Scenario (USD Billion)
  • Table 12.26: Glanatec™ (Ripasudil / K-115) Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.27: Glanatec™ (Ripasudil / K-115) Sales Forecast: Base Scenario (USD Billion)
  • Table 12.28: Vesneo™ (Latanoprostene bunod) Sales Forecast: Base Scenario (USD Billion)
  • Table 12.29: Vesneo™ (Latanoprostene bunod) Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.30: Vesneo™ (Latanoprostene bunod) Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.31: Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Base Scenario (USD Billion)
  • Table 12.32: Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.33: Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.34: Trabodenoson (INO-8875) Sales Forecast: Base Scenario (USD Billion)
  • Table 12.35: Trabodenoson (INO-8875) Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.36: Trabodenoson (INO-8875) Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.37: Roclatan™ (PG324) Sales Forecast: Base Scenario (USD Billion)
  • Table 12.38: Roclatan™ (PG324) Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.39: Roclatan™ (PG324) Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.40: DE-117 Sales Forecast: Base Scenario (USD Billion)
  • Table 12.41: DE-117 Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.42: DE-117 Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.43: Sustained Release Devices Sales Forecast: Base Scenario (USD Billion)
  • Table 12.44: Sustained Release Devices Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.45: Sustained Release Devices Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.46: Bimatoprost SR Sales Forecast: Base Scenario (USD Billion)
  • Table 12.47: Bimatoprost SR Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.48: Bimatoprost SR Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.49: Helios™ Insert (Bimatoprost Ring) Sales Forecast: Base Scenario (USD Billion)
  • Table 12.50: Helios™ Insert (Bimatoprost Ring) Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.51: Helios™ Insert (Bimatoprost Ring) Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.52: Punctal Plug Delivery System Sales Forecast: Base Scenario (USD Billion)
  • Table 12.53: Punctal Plug Delivery System Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.54: Punctal Plug Delivery System Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.55: ENV515 Sales Forecast: Base Scenario (USD Billion)
  • Table 12.56: ENV515 Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.57: ENV515 Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.58: OTX-TP Sales Forecast: Base Scenario (USD Billion)
  • Table 12.59: OTX-TP Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.60: OTX-TP Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.61: iDose™ Sales Forecast: Base Scenario (USD Billion)
  • Table 12.62: iDose™ Sales Forecast: Optimistic Scenario (USD Billion)
  • Table 12.63: iDose™ Sales Forecast: Conservative Scenario (USD Billion)
  • Table 12.64: Novel Surgical Devices Market, 2016 - 2026: Base Scenario (USD Billion)
  • Table 12.65: Novel Surgical Devices Market, 2016 - 2026: Optimistic Scenario (USD Billion)
  • Table 12.66: Novel Surgical Devices Market, 2016 - 2026: Conservative Scenario (USD Billion)
  • Table 12.67: MIGS Devices Market, 2016 - 2026: Base Scenario (USD Billion)
  • Table 12.68: MIGS Devices Market, 2016 - 2026: Optimistic Scenario (USD Billion)
  • Table 12.69: MIGS Devices Market, 2016 - 2026: Conservative Scenario (USD Billion)
  • Table 12.70: Non-MIGS Devices Market, 2016 - 2026: Base Scenario (USD Billion)
  • Table 12.71: Non-MIGS Devices Market, 2016 - 2026: Optimistic Scenario (USD Billion)
  • Table 12.72: Non-MIGS Devices Market, 2016 - 2026: Conservative Scenario (USD Billion)
  • Table 12.73: Non-MIGS Devices Market, 2026: Distribution by Device Category
  • Table 12.74: Glaucoma Therapies Market: Distribution by Treatment Modalities, 2016, 2021, and 2026 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. AC Immune
  • 2. ACADIA Pharmaceuticals
  • 3. Acorn Biomedical
  • 4. Actavis
  • 5. Aerie Pharmaceuticals
  • 6. Alcon Laboratories
  • 7. Alcon Research
  • 8. Allegro Investment Fun
  • 9. Allergan
  • 10. Allysta Pharmaceuticals
  • 11. Alta Partners
  • 12. Altacor
  • 13. Amakem Therapeutics
  • 14. Amgen
  • 15. Amorphex Therapeutics
  • 16. Amoun Pharmaceutical
  • 17. AqueSys
  • 18. Ascension Health Ventures
  • 19. Ascension Ventures
  • 20. AYUMI Pharmaceutical
  • 21. Bascom Palmer Eye Institute
  • 22. Bausch & Lomb
  • 23. Bayer
  • 24. Beaver-Visitec International
  • 25. Belgian Investment Federal Fund
  • 26. BioAxone BioSciences
  • 27. Bio-Light Life Sciences
  • 28. BioWin
  • 29. Caisse de depot et placement du Quebec
  • 30. Can-Fite BioPharma
  • 31. Capricorn Health-Tech Fund NV
  • 32. Care Capital
  • 33. Clarus Ventures
  • 34. Coherent
  • 35. Coronis Partners
  • 36. Cristalens
  • 37. Crown Venture Fund
  • 38. D. Western Therapeutics Institute
  • 39. D.O.R.C. International
  • 40. Deerfield Management Company
  • 41. Delphi Ventures
  • 42. Dendreon
  • 43. Device Technologies
  • 44. Devon Park Bioventures
  • 45. EDBI
  • 46. Ellex
  • 47. Ellex iScience
  • 48. Envisia Therapeutics
  • 49. Ergo-Prevent
  • 50. EVS Glaucoma Therapeutics
  • 51. Eye Sonix
  • 52. Eye Tech Care
  • 53. Financière Spin-off Luxembourgeoise (INVESTSUD Group)
  • 54. Fond Européen des Matériaux
  • 55. Foresite Capital
  • 56. Forest Laboratories
  • 57. ForSight VISION5
  • 58. Fuji Laboratory
  • 59. GBS Ventures
  • 60. GlaucoPharm
  • 61. Glaukos
  • 62. Glautec
  • 63. Graybug Vision
  • 64. Handok
  • 65. Healionics Corporation
  • 66. Hercules Technology Growth Capital
  • 67. Hicks Equity Partners
  • 68. Horizon Technology Finance Corporation
  • 69. Hospital Clinico San Carlos
  • 70. Hoya Group
  • 71. Icon Bioscience
  • 72. InMed Pharmaceuticals
  • 73. InnFocus
  • 74. Innovative Therapie und Diagnostik GmbH
  • 75. Inotek Pharmaceuticals
  • 76. InSite Vision
  • 77. International Medical Distribution
  • 78. InView Medical
  • 79. IOPtima
  • 80. Iridex Corporation
  • 81. Isarna Therapeutics
  • 82. iScience Interventional
  • 83. Iskowitz Instrumental SRL
  • 84. iSTAR Medical
  • 85. Ivantis
  • 86. Kadmon
  • 87. Kala Pharmaceuticals
  • 88. Kowa Company
  • 89. Leo Lens Technology
  • 90. Lexicon Pharmaceuticals
  • 91. Makina Optik Ticaret
  • 92. Marathon
  • 93. Mati Therapeutics
  • 94. McGee Eye Institute
  • 95. MedImmune Ventures
  • 96. Medisurg
  • 97. Meditor Capital Management
  • 98. MemorialCare Innovation Fund
  • 99. Merck & Co.
  • 100.MicroOptx Medical
  • 101.Miller School of Medicine
  • 102.Mitsubishi UFJ Capital
  • 103.Namur Invest - Preface
  • 104.NEMUS Bioscience
  • 105.Neomedix
  • 106.New Enterprise Associates
  • 107.New World Medical
  • 108.NicOx
  • 109.Novaliq GmbH
  • 110.Novartis
  • 111.Ocular Therapeutix
  • 112.Oculis Pharma
  • 113.OftalMedica srl
  • 114.OHR Pharmaceutical
  • 115.Ono Pharmaceuticals
  • 116.OphthaliX
  • 117.Ophthalmos
  • 118.Osage University
  • 119.Otsuka Pharmaceutical
  • 120.Oxford BioMedica
  • 121.Palobiofarma
  • 122.Peregrine Ophthalmic
  • 123.Pfizer
  • 124.Pioneer Pharma
  • 125.Pitango Venture Capital
  • 126.New Enterprise Associates (NEA)
  • 127.Polyactiva
  • 128.pSivida
  • 129.Radikal Therapeutics
  • 130.Ramot at Tel Aviv University
  • 131.Regeneron
  • 132.Replenish
  • 133.Rheon Medical
  • 134.Rho Ventures
  • 135.Roche
  • 136.Rosellini Scientific Benelux
  • 137.Saints Capital Everest
  • 138.Salix
  • 139.Sanoculis
  • 140.Sanofi
  • 141.Santen Pharmaceutical
  • 142.Scientific Health Development Partners
  • 143.Senju Pharmaceutical
  • 144.Shire
  • 145.Showa Yakuhin
  • 146.Sight Sciences
  • 147.Société Régionale d'Investissement de Wallonie (SRIW)
  • 148.Sofinnova Ventures
  • 149.SOLX
  • 150.STAAR Surgical
  • 151.Sun Pharma company
  • 152.Sylentis
  • 153.Technomix SA
  • 154.Tisbury Pharmaceuticals
  • 155.Tokyo New Drug Research Laboratories
  • 156.TPG Biotech
  • 157.Transcend Medical
  • 158.Ube Industries
  • 159.University of Miami
  • 160.University of Oklahoma
  • 161.University of Washington
  • 162.Valeant Pharmaceuticals International
  • 163.Vertex Ventures
  • 164.Wakamoto
  • 165.Yotsuya Shirato Eye Clinic
Back to Top